Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets

Par Conseil national de recherches du Canada

DOI	Trouver le DOI : https://doi.org/10.1016/j.celrep.2013.08.028
Auteur	Rechercher : Zaman, N.¹; Rechercher : Li, L.; Rechercher : Jaramillo, M.¹; Rechercher : Sun, Z.; Rechercher : Tibiche, C.¹; Rechercher : Banville, M.¹; Rechercher : Collins, C.¹; Rechercher : Trifiro, M.; Rechercher : Paliouras, M.; Rechercher : Nantel, A.¹; Rechercher : O'Connor-McCourt, M.¹; Rechercher : Wang, E.¹
Affiliation	Conseil national de recherches du Canada
Format	Texte, Article
Sujet	antineoplastic agent; bms 536924; bosutinib; docetaxel; erlotinib; nutlin 3; protein kinase B inhibitor; rapamycin; rdea 119; tamoxifen; tanespimycin; tcs 2312; tozasertib; unclassified drug; breast cancer; cancer cell; cancer classification; cell proliferation; cell survival; copy number variation; drug sensitivity; drug targeting; exome; gene identification; gene mutation; gene sequence; genetic screening; human cell; mutation; signal transduction; tumor gene
Résumé	Individual cancer cells carry a bewildering number ofdistinct genomic alterations (e.g., copy number variations and mutations), making it a challenge touncover genomic-driven mechanisms governing tumorigenesis. Here, we performed exome sequencing on several breast cancer cell lines that represent two subtypes, luminal and basal. We integrated these sequencing data and functional RNAi screening data (for the identification of genes that are essential for cell proliferation and survival) onto a human signaling network. Two subtype-specific networks that potentially represent core-signaling mechanisms underlying tumorigenesis were identified. Within both networks, we found that genes were differentially affected in different cell lines; i.e., in some cell lines a gene was identified through RNAi screening, whereas in others it was genomically altered. Interestingly, we found that highly connected network genes could be used to correctly classify breast tumors into subtypes on the basis of genomic alterations. Further, the networks effectively predicted subtype-specific drug targets, which were experimentally validated. © 2013 The Authors.
Date de publication	2013
Dans	Cell Reports 5, nº 1 (2013) : 216–223.
Langue	anglais
Publications évaluées par des pairs	Oui
Numéro NPARC	21270576
Exporter la notice	Exporter en format RIS
Signaler une correction	Signaler une correction (s'ouvre dans un nouvel onglet)
Identificateur de l’enregistrement	6f7d4adc-37d5-4bf8-9e45-130377e20eb8
Enregistrement créé	2014-02-17
Enregistrement modifié	2020-04-22

Date de modification :: 2024-06-30